ifosfamide has been researched along with Adverse Drug Event in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 7.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "Ifosfamide used in the treatment of pediatric solid tumors is known to have serious adverse effects, including acute pancreatitis, a rare complication of therapy." | 7.76 | Acute pancreatitis induced by ifosfamide therapy. ( Agarwala, S; Bhatnagar, V; Garg, R, 2010) |
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 3.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "Ifosfamide used in the treatment of pediatric solid tumors is known to have serious adverse effects, including acute pancreatitis, a rare complication of therapy." | 3.76 | Acute pancreatitis induced by ifosfamide therapy. ( Agarwala, S; Bhatnagar, V; Garg, R, 2010) |
| "Ifosfamide infusion was stopped immediately after the IIE occurrence, and patients underwent renal function correction with hydration." | 1.62 | Methylene blue and ifosfamide-induced encephalopathy: Myth or reality? ( Abahssain, H; Errihani, H; Essangri, H; Fadhil, FZ; Guessous, F; Meddah, B; Moukafih, B; Mrabti, H; Souadka, A, 2021) |
| "Since 1985, we introduced a modified combination of etoposide, ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell tumors with the aim to reduce toxic effect while maintaining efficacy over the original regimen." | 1.39 | Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. ( Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Pizzocaro, G; Raggi, D; Salvioni, R; Stagni, S; Torelli, T, 2013) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed." | 1.33 | Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. ( Craft, A; Juergens, C; Juergens, H; Lewis, I; Michon, J; Oberlin, O; Paulussen, M; Weston, C; Whelan, J; Zoubek, A, 2006) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Abahssain, H | 1 |
| Moukafih, B | 1 |
| Essangri, H | 1 |
| Mrabti, H | 1 |
| Meddah, B | 1 |
| Guessous, F | 1 |
| Fadhil, FZ | 1 |
| Souadka, A | 1 |
| Errihani, H | 1 |
| Necchi, A | 1 |
| Nicolai, N | 1 |
| Mariani, L | 1 |
| Raggi, D | 1 |
| Farè, E | 1 |
| Giannatempo, P | 1 |
| Catanzaro, M | 1 |
| Biasoni, D | 1 |
| Torelli, T | 1 |
| Stagni, S | 1 |
| Milani, A | 1 |
| Piva, L | 1 |
| Pizzocaro, G | 1 |
| Gianni, AM | 1 |
| Salvioni, R | 1 |
| Lin, HH | 1 |
| Lin, JN | 1 |
| Jordan, K | 1 |
| Jahn, F | 1 |
| Jahn, P | 1 |
| Behlendorf, T | 1 |
| Stein, A | 1 |
| Ruessel, J | 1 |
| Kegel, T | 1 |
| Schmoll, HJ | 1 |
| Garg, R | 1 |
| Agarwala, S | 1 |
| Bhatnagar, V | 1 |
| Chen, N | 1 |
| Hanly, L | 1 |
| Rieder, M | 1 |
| Yeger, H | 1 |
| Koren, G | 1 |
| Kosmas, C | 1 |
| Vorgias, G | 1 |
| Tsakonas, G | 1 |
| Politis, P | 1 |
| Daladimos, T | 1 |
| Panagiotidi, E | 1 |
| Papachrysanthou, T | 1 |
| Moschovis, D | 1 |
| Kalinoglou, N | 1 |
| Tsavaris, N | 1 |
| Karabelis, A | 1 |
| Mylonakis, N | 1 |
| Ogura, K | 1 |
| Goto, T | 1 |
| Imanishi, J | 1 |
| Shinoda, Y | 1 |
| Okuma, T | 1 |
| Tsuda, Y | 1 |
| Kobayashi, H | 1 |
| Akiyama, T | 1 |
| Hirata, M | 1 |
| Yamamoto, A | 1 |
| Kawano, H | 1 |
| He, A | 1 |
| Qi, W | 1 |
| Huang, Y | 1 |
| Sun, Y | 1 |
| Shen, Z | 1 |
| Zhao, H | 1 |
| Yang, Y | 1 |
| Yao, Y | 1 |
| Cavaletti, G | 1 |
| Bogliun, G | 1 |
| Marzorati, L | 1 |
| Zincone, A | 1 |
| Piatti, M | 1 |
| Colombo, N | 1 |
| Parma, G | 1 |
| Lissoni, A | 1 |
| Fei, F | 1 |
| Cundari, S | 1 |
| Zanna, C | 1 |
| Fan, SK | 1 |
| Wang, YG | 1 |
| Juergens, C | 1 |
| Weston, C | 1 |
| Lewis, I | 1 |
| Whelan, J | 1 |
| Paulussen, M | 1 |
| Oberlin, O | 1 |
| Michon, J | 1 |
| Zoubek, A | 1 |
| Juergens, H | 1 |
| Craft, A | 1 |
| Gottfried, M | 1 |
| Ramlau, R | 1 |
| Krzakowski, M | 1 |
| Ziolo, G | 1 |
| Olechnowicz, H | 1 |
| Koubkova, L | 1 |
| Dahabreh, J | 1 |
| Szczesna, A | 1 |
| Vivanco, GL | 1 |
| Perng, RP | 1 |
| Carpagnano, F | 1 |
| Leong, SS | 1 |
| Fittipaldo, A | 1 |
| De Almeida, C | 1 |
| Aubert, D | 1 |
| Grunenwald, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)[NCT00020566] | Phase 3 | 1,200 participants (Anticipated) | Interventional | 2001-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ifosfamide and Adverse Drug Event
| Article | Year |
|---|---|
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Co | 2011 |
Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2008 |
15 other studies available for ifosfamide and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Diseases; Creatinine; Drug-Related Side Effect | 2021 |
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug- | 2013 |
Tender nodules on the palms and soles after chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Epiru | 2008 |
Acute pancreatitis induced by ifosfamide therapy.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ca | 2010 |
The effect of N-acetylcysteine on the antitumor activity of ifosfamide.
Topics: Acetylcysteine; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Drug Interaction | 2011 |
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Topics: Adnexal Diseases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplat | 2011 |
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Di | 2013 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytid | 2013 |
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Si | 2003 |
Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
Topics: Algorithms; Anti-HIV Agents; Antineoplastic Agents, Alkylating; Child, Preschool; Clinical Trials, P | 2006 |
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Clinical T | 2006 |